Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

The Translational Research in Maternal and Pediatric Pharmacology and Therapeutics opportunity, identified as PAR-28-059, is a forecasted federal grant opportunity from the Department of Health and Human Services through the National Institutes of Health. The opportunity is associated with Assistance Listing 93.865, Child Health and Human Development Extramural Research. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, describes the planned funding opportunity as part of its stewardship of Congressionally mandated activities under the Best Pharmaceuticals for Children Act and its implementation of recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The forecast was posted on August 20, 2026, and applications are not being solicited at this time. NICHD intends to renew and publish a Notice of Funding Opportunity to promote translational and clinical research involving pregnant women, lactating women, infants, children, and adolescents. The overall goal is to improve safe and effective precision therapeutics during pregnancy, lactation, and across childhood. The planned research has four stated objectives. These are to advance precision medicine through the development, testing, and implementation of novel tools, models, and other technologies; discover and develop novel therapeutics or enhance the use of existing drugs to provide safer and more effective medications; enhance patient-provider communications concerning drug effectiveness and safety risks; and optimize the dissemination, implementation, sustainment, and scale-up of evidence-based interventions for the identified patient populations. The forecast identifies the funding instrument as a grant and the funding activity category as Health. It does not state an estimated total program funding amount, award ceiling, award floor, or expected number of awards. No cost sharing or matching requirement applies according to the forecast. The available forecast also does not provide detailed allowable or prohibited cost rules, indirect cost limitations, subaward limitations, or a defined period of performance. These details may be established when the full Notice of Funding Opportunity is published. Eligible applicants encompass a broad range of organizational types. They include state governments, county governments, city or township governments, special district governments, independent school districts, public housing authorities and Indian housing authorities, federally recognized Native American tribal governments, Native American tribal organizations, public and state controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status other than institutions of higher education, small businesses, and for-profit organizations other than small businesses. Additional eligible applicants identified in the forecast include Indian or Native American tribal governments other than federally recognized governments, eligible agencies of the federal government, U.S. territories or possessions, faith-based or community-based organizations, regional organizations, and non-domestic entities or foreign institutions. The forecast does not state a U.S. state-specific restriction. The opportunity remains in the forecast stage, and applications are not currently being solicited. Grants.gov lists an estimated post date of March 31, 2027 and an estimated application due date of July 9, 2027. Because the opportunity is forecasted rather than presently open, applicants should use these dates as anticipated rather than final dates. The supplied forecast does not identify a required letter of intent, concept paper, pre-proposal, notice of intent, or other pre-application gating requirement. It also does not provide application questions, required uploads, narrative components, evaluation criteria, review factors, or other detailed submission mechanics. Those requirements are expected to depend on the future Notice of Funding Opportunity and are not available in the supplied forecast. The estimated award date is April 1, 2028, and the estimated project start date is also April 1, 2028, with fiscal year 2028 identified for the opportunity. No archive date is provided. The source does not state that the opportunity will recur annually, biennially, quarterly, or on another recurring schedule, so no recurrence is established from the available forecast. Questions may be directed by email to the Obstetric and Pediatric Pharmacology and Therapeutics Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development at nichd_opptb_nofos@mail.nih.gov. No individual grantor contact name or telephone number is provided.

Align the proposed research with the stated goal of improving safe and effective precision therapeutics during pregnancy, lactation, or childhood and clearly connect the work to the stated priorities involving precision medicine tools and technologies, novel or improved therapeutics, patient-provider communication about drug effectiveness and safety risks, or dissemination, implementation, sustainment, and scale-up of evidence-based interventions.